2006
Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients
Liu PP, Maggioni A, Velazquez EJ. Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients. Journal Of The Renin-Angiotensin-Aldosterone System 2006, 7: s19-s22. PMID: 16986231, DOI: 10.3317/jraas.2006.019.Peer-Reviewed Original ResearchConceptsAng II receptor blockersHeart failureLV dysfunctionMyocardial infarctionStrong therapeutic rationaleUse of valsartanII receptor blockersLeft ventricular dysfunctionHeart failure patientsPost-MI patientsMain effector mechanismPost-myocardial infarctionLarge-scale trialsRAAS blockadeAldosterone systemReceptor blockersVentricular dysfunctionAssociated morbidityFailure patientsFrequent complicationSuch patientsACE inhibitorsSignificant morbiditySuch therapyDisease progression
2004
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry
Velazquez EJ, Francis GS, Armstrong PW, Aylward PE, Diaz R, O'Connor CM, White HD, Henis M, Rittenhouse LM, Kilaru R, van Gilst W, Ertl G, Maggioni AP, Spac J, Weaver WD, Rouleau JL, McMurray JJ, Pfeffer MA, Califf RM. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. European Heart Journal 2004, 25: 1911-1919. PMID: 15522470, DOI: 10.1016/j.ehj.2004.08.006.Peer-Reviewed Original ResearchConceptsHospital heart failureVentricular systolic dysfunctionHeart failureMyocardial infarctionBaseline variablesSystolic dysfunctionMI patientsConsecutive MI patientsBaseline risk factorsHospital mortality rateMI populationAcute myocardial infarctionEarly myocardial infarctionLong-term riskHospital mortalityCardiovascular eventsHospital deathHazard ratioLonger hospitalisationBaseline presenceMedical therapySuch patientsContemporary incidenceMore complicationsRisk factors